4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $30.50 Consensus Target Price from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have received a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average […]

Related Keywords

Canada ,Alger ,Algeria ,Leerink Partnrs ,David Kirn ,Lazard Asset Management ,Royal Bank ,International Assets Investment Management ,Daiwa Securities Group Inc ,Nasdaq ,D Molecular Therapeutics Inc ,Securities Exchange Commission ,Cantor Fitzgerald ,Fred Alger Management ,D Molecular Therapeutics Company Profile ,Molecular Therapeutics ,Get Free Report ,Marketbeat Ratings ,Global Investors Lp Viking ,Exchange Commission ,Asset Management ,Assets Investment Management ,Securities Group ,Molecular Therapeutics Company ,Get Free ,Molecular Therapeutics Daily ,4d Molecular Therapeutics ,Nasdaq Fdmt ,Fdmt ,Medical ,Ratings ,Consensus ,